Two Directors of Search & Evaluation to lead strategic sourcing and evaluation of external innovation opportunities in Hematology, and Cardiovascular/Renal therapeutic areas. Embedded within each Therapeutic Area Leadership Team (TALT), these leaders will identify and advance high-potential assets from preclinical through Phase 1 clinical stages, shape early partnering strategies, and drive transactions in collaboration with Business Development
MainResponsibilities & Accountabilities
Serve as the senior Early S&E leader within the TALT, influencing therapeutic strategy and ensuring external innovation priorities are integrated into portfolio planning.
Lead proactive sourcing and scouting efforts for preclinical and Phase 1 assets, building a robust pipeline of opportunities aligned with TA strategy.
Co-lead internal meetings (with Late Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations
Develop and execute early partnering strategies, including onboarding approaches and competitive positioning for priority assets.
Drive cross-functional due diligence for each opportunity, coordinating scientific, clinical, regulatory, and commercial assessments to inform governance decisions.
Transaction Execution: Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution
Represent the TA externally, leading sourcing activities at specialized conferences and cultivating relationships with biotech, academia, and investment communities.
Qualifications & Experience Requirements
Significant tenure in biopharma with significant experience in external innovation, search & evaluation, or business development.
Advanced degree required (PhD, MD, or equivalent).
Must have Deep scientific expertise in Hematology or Cardiovascular/Renal therapeutic areas.
Proven track record of leading due diligence and closing early-stage deals.
Strong network within biotech, academia, and pharma BD organizations.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.
To learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit https://www.csl.com/ and CSL Plasma at https://www.cslplasma.com/.
Our Benefits
For more information on CSL benefits visit How CSL Supports Your Well-being | CSL.
You Belong at CSL
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out. By celebrating our differences and creating a culture of curiosity and empathy, we are able to better understand and connect with our patients and donors, foster strong relationships with our stakeholders, and sustain a diverse workforce that will move our company and industry into the future.
To learn more about inclusion and belonging visit https://www.csl.com/careers/inclusion-and-belonging
Equal Opportunity Employer
CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please visit https://www.csl.com/accessibility-statement.
csl